-
Recent Posts
- Disappointing Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
- Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-Cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (AHUS)
- Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis
- AstraZeneca Reports Full Results from DECLARE-TIMI 58 Cardiovascular Outcomes Trial for FARXIGA (dapagliflozin)
- Lokelma approved in the US for the treatment of adults with hyperkalemia
Recent Comments
Archives
Categories
Meta
Monthly Archives: November 2018
AstraZeneca Reports Full Results from DECLARE-TIMI 58 Cardiovascular Outcomes Trial for FARXIGA (dapagliflozin)
November 12, 2018; Reproduced from StreetInsider AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at the American Heart Association (AHA) Scientific Sessions … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment
Lokelma approved in the US for the treatment of adults with hyperkalemia
On May 18, 2018 AstraZeneca announced the FDA approval of their new drug Lokelma, for the treatment of hyperkalemia. The full new release is reproduced below: The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment